The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease

This publication has 30 references indexed in Scilit:

• Association of Cholesteryl Ester Transfer Protein– Taq IB Polymorphism With Variations in Lipoprotein Subclasses and Coronary Heart Disease Risk
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2000
• Action of Atorvastatin in Combined Hyperlipidemia
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2000
• Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
  New England Journal of Medicine, 1998
• PLASMA LIPID TRANSFER PROTEINS, HIGH-DENSITY LIPOPROTEINS, AND REVERSE CHOLESTEROL TRANSPORT
  Annual Review of Nutrition, 1998
• A Computer-Assisted Management Program for Antibiotics and Other Antiinfective Agents
  New England Journal of Medicine, 1998
• Heterogeneity at theCETPGene Locus
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1997
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
  The Lancet, 1994
• Relation of polymorphisms in the cholesteryl ester transfer protein gene to transfer protein activity and plasma lipoprotein levels in alcohol drinkers
  Atherosclerosis, 1994
• Atherosclerosis Regression, Plaque Disruption, and Cardiovascular Events: A Rationale for Lipid Lowering in Coronary Artery Disease
  Annual Review of Medicine, 1993
• Inhibition of cholesteryl ester transfer protein activity by monoclonal antibody. Effects on cholesteryl ester formation and neutral lipid mass transfer in human plasma.
  Journal of Clinical Investigation, 1989